PUBLISHER: TechNavio | PRODUCT CODE: 2144843
PUBLISHER: TechNavio | PRODUCT CODE: 2144843
Global RNAi Drug Delivery Market 2026-2030
The global RNAi drug delivery market is forecasted to grow by USD 184606.4 mn during 2025-2030, accelerating at a CAGR of 20.0% during the forecast period. The report on the global RNAi drug delivery market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by focused delivery technologies enable precision genetic silencing, expanding chronic disease burdens drive target validation, strategic corporate collaborations accelerate early commercial pipelines.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 17.9% |
| CAGR | 20% |
| Incremental Value | $184606.4 mn |
Technavio's global RNAi drug delivery market is segmented as below:
By Technology
- Nanoparticle drug delivery
- Pulmonary drug delivery
- Nucleic acid drug delivery
- Aptamer drug delivery
By Application
- Infectious diseases
- Oncology
- Cardiology
- Neurology
- Others
By Route Of Administration
- Intravenous delivery
- Subcutaneous delivery
- Intrathecal
- Intramuscular
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the next generation conjugation formulations dominate pipeline development as one of the prime reasons driving the global RNAi drug delivery market growth during the next few years. Also, strategic out licensing partnerships accelerate enterprise commercialization and central nervous system delivery research expands neurological applications will lead to sizable demand in the market.
The report on the global RNAi drug delivery market covers the following areas:
- Global RNAi drug delivery market sizing
- Global RNAi drug delivery market forecast
- Global RNAi drug delivery market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global RNAi drug delivery market vendors that include Acuitas Therapeutics, ADARx Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Aptadel Therapeutics, Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., BioNTech SE, Calando Pharmaceuticals Inc., Enzene Biosciences Ltd., Genevant Sciences Corp., Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, OliX Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Switch Therapeutics Inc., Sylentis S.A., Takeda Pharmaceutical Ltd., Vir Biotechnology Inc.. Also, the global RNAi drug delivery market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global RNAi Drug Delivery Market 2020 - 2024
- Historic Market Size - Data Table on Global RNAi Drug Delivery Market 2020 - 2024 ($ million)
- 5.2 Technology segment analysis 2020 - 2024
- Historic Market Size - Technology Segment 2020 - 2024 ($ million)
- 5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.4 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global RNAi drug delivery market
- 6.2 Impact of geopolitical conflicts on global RNAi drug delivery market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Technology
- 8.1 Market segments
- 8.2 Comparison by Technology
- 8.3 Nanoparticle drug delivery - Market size and forecast 2025-2030
- 8.4 Pulmonary drug delivery - Market size and forecast 2025-2030
- 8.5 Nucleic acid drug delivery - Market size and forecast 2025-2030
- 8.6 Aptamer drug delivery - Market size and forecast 2025-2030
- 8.7 Market opportunity by Technology
- Market opportunity by Technology ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- 9.2 Comparison by Application
- 9.3 Infectious diseases - Market size and forecast 2025-2030
- 9.4 Oncology - Market size and forecast 2025-2030
- 9.5 Cardiology - Market size and forecast 2025-2030
- 9.6 Neurology - Market size and forecast 2025-2030
- 9.7 Others - Market size and forecast 2025-2030
- 9.8 Market opportunity by Application
- Market opportunity by Application ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- 10.2 Comparison by Route of Administration
- 10.3 Intravenous delivery - Market size and forecast 2025-2030
- 10.4 Subcutaneous delivery - Market size and forecast 2025-2030
- 10.5 Intrathecal - Market size and forecast 2025-2030
- 10.6 Intramuscular - Market size and forecast 2025-2030
- 10.7 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Australia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.5 Turkey - Market size and forecast 2025-2030
- 12.6.6 South Africa - Market size and forecast 2025-2030
- 12.6.7 Israel - Market size and forecast 2025-2030
- 12.6.8 Argentina - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Focused delivery technologies enable precision genetic silencing
- Expanding chronic disease burdens drive target validation
- Strategic corporate collaborations accelerate early commercial pipelines
- 13.2 Market challenges
- Targeted extrahepatic tissue delivery barriers restrict reach
- High manufacturing overhead and oligonucleotide synthesis costs
- Transient gene silencing requires persistent lifetime dosing
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Next generation conjugation formulations dominate pipeline development
- Strategic out licensing partnerships accelerate enterprise commercialization
- Central nervous system delivery research expands neurological applications
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc. - Overview
- Arrowhead Pharmaceuticals Inc. - Product / Service
- Arrowhead Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.5 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 15.6 Calando Pharmaceuticals Inc.
- Calando Pharmaceuticals Inc. - Overview
- Calando Pharmaceuticals Inc. - Product / Service
- Calando Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.7 Enzene Biosciences Ltd.
- Enzene Biosciences Ltd. - Overview
- Enzene Biosciences Ltd. - Product / Service
- Enzene Biosciences Ltd. - Key offerings
- SWOT
- 15.8 Genevant Sciences Corp.
- Genevant Sciences Corp. - Overview
- Genevant Sciences Corp. - Product / Service
- Genevant Sciences Corp. - Key offerings
- SWOT
- 15.9 Ionis Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc. - Overview
- Ionis Pharmaceuticals Inc. - Product / Service
- Ionis Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.10 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.11 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.12 OliX Pharmaceuticals Inc.
- OliX Pharmaceuticals Inc. - Overview
- OliX Pharmaceuticals Inc. - Product / Service
- OliX Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.13 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.14 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.15 Switch Therapeutics Inc.
- Switch Therapeutics Inc. - Overview
- Switch Therapeutics Inc. - Product / Service
- Switch Therapeutics Inc. - Key offerings
- SWOT
- 15.16 Sylentis S.A.
- Sylentis S.A. - Overview
- Sylentis S.A. - Product / Service
- Sylentis S.A. - Key offerings
- SWOT
- 15.17 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Vir Biotechnology Inc.
- Vir Biotechnology Inc. - Overview
- Vir Biotechnology Inc. - Product / Service
- Vir Biotechnology Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
